203Induction of systemic PSA-specific T cell responses in prostate cancer patients after high-intensity focused ultrasound treatment

2005 ◽  
Vol 4 (3) ◽  
pp. 53 ◽  
Author(s):  
H.J. Kiel ◽  
S. Thueroff ◽  
M. Laumer ◽  
J. Heymann ◽  
C. Chaussy ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
T Cell ◽  
Cancer Patients ◽  
High Intensity ◽  
Focused Ultrasound ◽  
T Cell Responses ◽  
High Intensity Focused Ultrasound ◽  
Ultrasound Treatment ◽  
Cell Responses

Analysis of PSA-Specific T-Cell Responses of Prostate Cancer Patients Given a PSA-Based Vaccine on a Clinical Trial

2003 ◽  
Author(s):  
James Gulley ◽  
William Dahut ◽  
Philip M. Arlen ◽  
Kwong Tsang ◽  
Jeffrey Schlom
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
T Cell ◽  
Cancer Patients ◽  
T Cell Responses ◽  
Cell Responses

scholarly journals Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients

2011 ◽  
Vol 61 (2) ◽  
pp. 169-179 ◽  
Author(s):  
Ray Wilkinson ◽  
Katherine Woods ◽  
Rachael D’Rozario ◽  
Rebecca Prue ◽  
Frank Vari ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
T Cell ◽  
Cancer Patients ◽  
Signal Peptide ◽  
T Cell Responses ◽  
Cytotoxic T Cell ◽  
Cell Responses ◽  
Healthy Donors ◽  
Kallikrein 4 ◽  
Cytotoxic T Cell Responses

RNA Based Cancer Vaccines - Clinical Trials in Patients with Prostate Cancer and Malignant Melanoma.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1805-1805
Author(s):  
Gunnar Kvalheim ◽  
Steinar Aamdal ◽  
Gustav Gaudernack
Keyword(s):  
Prostate Cancer ◽  
T Cell ◽  
Malignant Melanoma ◽  
Cancer Patients ◽  
Ex Vivo ◽  
T Cell Responses ◽  
T Cell Response ◽  
Patient Specific ◽  
Cell Responses ◽  
Melanoma Patients

Abstract Anti-tumour vaccines targeting the entire tumour antigen repertoire represent an attractive immunotherapeutic approach. This repertoire is present in the total mRNA isolated from the tumour. The mRNA from each cancer patient may be amplified and thus overcome the problem of limitation of material that has hampered the development of individualized vaccines. We have developed immuno-gene-therapy for malignant melanoma and prostate cancer. Monocyte-derived dendritic dells are transfected with autologous melanoma-mRNA or mRNA from three prostate cancer cell lines (DU-145, LN-CaP and PC-3). The vaccines may generate T cell responses against a broad repertoire of tumor-associated epitopes, and the melanoma approach moreover target patient-specific tumor antigens. Effective protocols were established for mRNA-transfection by square wave electroporation and for generation of clinical grade dendritic cells. A full scale preclinical evaluation demonstrated in vitro T cell responses in 6/6 advanced melanoma patients. The responses were specific to antigens encoded by the transfected tumor-mRNA. Recently, we have conducted two phase I/II trials, in advanced malignant melanoma and androgen-resistant prostate cancer. Successful vaccine preparations were obtained for all 41 patients elected. No serious adverse effects were observed. Specific T cell responses (T cell proliferation and/or IFNγ ELISPOT) were demonstrated in 9/19 evaluable melanoma patients and in 12/19 prostate cancer patients. The response rates were higher for patients receiving intradermal vaccination, compared to intranodal injection. Thirteen prostate cancer patients developed a decrease in log-slope PSA. The PSA-response was significantly related to the T cell response (p=0,002). We conclude that the tumour mRNA based DC-vaccine is feasible and safe, and that T cell responses are elicited in about 50% of patients. In the next generation clinical protocols, patients will undergo Treg depletion by chemotherapy (Temozolomide) prior to DC vaccination. Subsequently, T cells will be expanded ex vivo using the Dynabeads Clin Ex Vivo system before re-infusion into the patients.

Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer

2006 ◽  
Vol 24 (5) ◽  
pp. 585-590 ◽  
Author(s):  
Andreas Blana ◽  
Sebastian Rogenhofer ◽  
Roman Ganzer ◽  
Peter J. Wild ◽  
Wolf F. Wieland ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Ultrasound Treatment ◽  
Localized Prostate Cancer

scholarly journals Assessing high‐intensity focused ultrasound treatment of prostate cancer with hyperpolarized 13 C dual‐agent imaging of metabolism and perfusion

2018 ◽  
Vol 32 (10) ◽  
Author(s):  
Jessie E. Lee ◽  
Chris J. Diederich ◽  
Robert Bok ◽  
Renuka Sriram ◽  
Romelyn Delos Santos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Ultrasound Treatment
Sign in / Sign up

Export Citation Format

Share Document